Assessing patients' risk of febrile neutropenia: Is there a correlation between physician-assessed risk and model-predicted risk?

Cancer Medicine

Volumn 4, Issue 8, 2015, Pages 1153-1160

  Lyman, Gary H ^a   Dale, David C ^b   Legg, Jason C ^c   Abella, Esteban ^c   Morrow, Phuong Khanh ^c   Whittaker, Sadie ^c   Crawford, Jeffrey ^d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c AMGEN INC   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Febrile neutropenia; Granulocyte colony stimulating factor; Neutropenia; Primary prophylaxis; Risk assessment; Risk factors; Risk model; Severe neutropenia

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; PREDNISONE; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CORRELATION ANALYSIS; ELECTRONIC MEDICAL RECORD; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL PREDICTED FEBRILE NEUTROPENIA RISK; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; ONCOLOGIST; PHYSICIAN; PHYSICIAN ASSESSED FEBRILE NEUTROPENIA RISK; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; VERY ELDERLY; CANCER STAGING; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; RISK; UNITED STATES; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PHYSICIANS; RISK; UNITED STATES; YOUNG ADULT;

EID: 85006226823     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.454     Document Type: Article

References (27)

1. Lyman, G. H., S. L. Michels, M. W. Reynolds, R. Barron, K. S. Tomic, and J. Yu . 2010. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555-5563.
2. Kuderer, N. M., D. C. Dale, J. Crawford, L. E. Cosler, and G. H. Lyman . 2006. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266.
3. Smith, T. J., J. Khatcheressian, G. H. Lyman, et al. 2006. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24:3187-3205.
4. Crawford, J., C. Caserta, and F. Roila . 2010. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann. Oncol. 21:v248-v251.
5. Lyman, G. H., C. H. Lyman, and O. Agboola . 2005. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427-437.
6. Crawford, J., D. C. Dale, N. M. Kuderer, et al. 2008. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl. Compr. Canc. Netw. 6:109-118.
7. Shayne, M., E. Culakova, M. S. Poniewierski, et al. 2007. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110:1611-1620.
8. Voog, E., J. Bienvenu, K. Warzocha, et al. 2000. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J. Clin. Oncol. 18:325-331.
9. Lyman, G. H., V. A. Morrison, D. C. Dale, J. Crawford, D. J. Delgado, and M. Fridman . 2003. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk. Lymphoma 44:2069-2076.
10. Laskey, R. A., M. S. Poniewierski, M. A. Lopez, et al. 2012. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol. Oncol. 125:625-630.
11. Blackwell, S., and J. Crawford . 1994. Filgrastim (r-metHuG-CSF) in the chemotherapy setting. Pp. 103-116 in G. Morstyn and T. M. Dexter, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. Marcel Dekker, New York, NY.
12. Lyman, G. H., N. M. Kuderer, J. Crawford, et al. 2011. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917-1927.
13. Vogel, C. L., M. Z. Wojtukiewicz, R. R. Carroll, et al. 2005. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 23:1178-1184.
14. Shao, J., and D. Tu . 1995. Pp. 386-392 The Jackknife and Bootstrap. Springer-Verlag, New York, NY.
15. Fisher, R. A. 1925. Statistical Methods for Research Workers. Hafner Press, London, UK.
16. Bonett, D. G., and T. A. Wright . 2000. Sample size requirement for estimating Pearson, Kendall, and Spearman correlations. Psychometrika 65:23-28.
17. Field, C. A., and A. H. Welsh . 2007. Bootstrapping clustered data. J. Roy. Stat. Soc. B 69:369-390.
18. Centers for Disease Control and Prevention. 2014. National diabetes statistics report, 2014. Available at http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. (accessed 10 March 2015).
19. Yoon, S. S., V. Burt, T. Louis, and M. D. Carroll . 2012. Hypertension among adults in the United States, 2009-2010. Available at http://www.cdc.gov/nchs/data/databriefs/db107.pdf. (accessed 10 March 2015).
20. Kuderer, N. M., and G. H. Lyman . 2011. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J. Natl Cancer Inst. 103:910-913.
21. Hanna, R. K., M. S. Poniewierski, R. A. Laskey, et al. 2013. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 129:74-80.
22. Lyman, G. H., D. C. Dale, D. Tomita, S. Whittaker, and J. Crawford . 2013. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res. Treat. 139:863-872.
23. National Comprehensive Cancer Network. 2013. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, version 2. National Comprehensive Cancer Network, Inc., Fort Washington, PA.
24. Aapro, M. S., J. Bohlius, D. A. Cameron, et al. 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47:8-32.
25. Salar, A., C. Haioun, F. G. Rossi, et al. 2012. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk. Res. 36:548-553.
26. Krzemieniecki, K., P. Sevelda, F. Erdkamp, et al. 2014. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy-findings from clinical practice. Support. Care Cancer 22:667-677.
27. Younis, T., D. Rayson, and K. Thompson . 2012. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support. Care Cancer 20:2523-2530.